Global and cell type-specific immunological hallmarks of severe dengue progression

Severe dengue (SD) is a major cause of morbidity and mortality impacting approximately 5 million of the 400 million people infected with dengue virus (DENV) annually. To define DENV target cells and immunological hallmarks of SD progression in children’s blood, we integrated virus-inclusive single cell RNA-Seq 2 (viscRNA-Seq 2) with functional assays. Beyond myeloid cells, in natural infection, B cells harbor replicating DENV capable of infecting permissive cells. Alterations in cell type abundance, gene and protein expression and secretion, and cell-cell communications point towards increased migration and inflammation in SD progressors (SDp). Concurrently, antigen presenting cells from SDp demonstrate intact uptake, yet impaired interferon responses and antigen presentation, in part DENV-modulated. Increased activation, regulation, and exhaustion of effector responses and expansion of HLA-DR-expressing, possibly compensatory, adaptive-like NK cells also characterize SDp. These findings reveal DENV target cells in the human blood and provide insight into SD pathogenesis beyond antibody-mediated enhancement.

[1]  J. Montoya,et al.  Magnitude and kinetics of the human immune cell response associated with severe dengue progression by single-cell proteomics , 2022, bioRxiv.

[2]  S. Kabra,et al.  Contrasting behavior between the three human monocyte subsets in dengue pathophysiology , 2022, iScience.

[3]  Aditya M. Rao,et al.  An 8-gene machine learning model improves clinical prediction of severe dengue progression , 2022, Genome Medicine.

[4]  J. Modiano,et al.  Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells , 2022, Frontiers in Immunology.

[5]  S. Sagan,et al.  Molecular Determinants of Flavivirus Virion Assembly. , 2021, Trends in biochemical sciences.

[6]  Jaime Fern'andez del R'io,et al.  Array programming with NumPy , 2020, Nature.

[7]  S. Vasudevan,et al.  Positive epistasis between viral polymerase and the 3′ untranslated region of its genome reveals the epidemiologic fitness of dengue virus , 2020, Proceedings of the National Academy of Sciences.

[8]  Mirjana Efremova,et al.  CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes , 2020, Nature Protocols.

[9]  A. Rothman,et al.  Analysis of cell-associated DENV RNA by oligo(dT) primed 5’ capture scRNAseq , 2020, Scientific Reports.

[10]  I. Rodenhuis-Zybert,et al.  Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection , 2019, Front. Immunol..

[11]  A. Muntasell,et al.  Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes , 2019, Front. Immunol..

[12]  B. Restrepo,et al.  Different phenotypes of non‐classical monocytes associated with systemic inflammation, endothelial alteration and hepatic compromise in patients with dengue , 2019, Immunology.

[13]  Francesco Vallania,et al.  A 20-Gene Set Predictive of Progression to Severe Dengue , 2019, Cell reports.

[14]  Vincent A. Traag,et al.  From Louvain to Leiden: guaranteeing well-connected communities , 2018, Scientific Reports.

[15]  A. Khromykh,et al.  Subgenomic flaviviral RNAs: What do we know after the first decade of research , 2018, Antiviral research.

[16]  K. Weeks,et al.  Pervasive tertiary structure in the dengue virus RNA genome , 2018, Proceedings of the National Academy of Sciences.

[17]  D. Kaufman,et al.  Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells , 2018, bioRxiv.

[18]  D. Gubler,et al.  Development of standard clinical endpoints for use in dengue interventional trials , 2018, PLoS neglected tropical diseases.

[19]  D. Davis,et al.  Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells , 2018, The Journal of cell biology.

[20]  G. Ogg,et al.  Regulatory T‐cells in acute dengue viral infection , 2018, Immunology.

[21]  M. Halloran,et al.  Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Halloran,et al.  Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.

[23]  S. Quake,et al.  Single-cell transcriptional dynamics of flavivirus infection , 2017, bioRxiv.

[24]  A. Rothman,et al.  Immune-mediated cytokine storm and its role in severe dengue , 2017, Seminars in Immunopathology.

[25]  K. Porter,et al.  NK cell degranulation as a marker for measuring antibody-dependent cytotoxicity in neutralizing and non-neutralizing human sera from dengue patients. , 2017, Journal of immunological methods.

[26]  J. Taubenberger,et al.  IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity , 2017, Science.

[27]  Julio Saez-Rodriguez,et al.  OmniPath: guidelines and gateway for literature-curated signaling pathway resources , 2016, Nature Methods.

[28]  S. A. de Oliveira,et al.  Circulating cytokines and chemokines associated with plasma leakage and hepatic dysfunction in Brazilian children with dengue fever. , 2015, Acta tropica.

[29]  P. V. Lakshmana Rao,et al.  Serum levels of IL-8, IFNγ, IL-10, and TGF β and their gene expression levels in severe and non-severe cases of dengue virus infection , 2015, Archives of Virology.

[30]  S. Halstead,et al.  Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. , 2014, Human pathology.

[31]  G. Ogg,et al.  Suppression of Virus Specific Immune Responses by IL-10 in Acute Dengue Infection , 2013, PLoS neglected tropical diseases.

[32]  E. Harris,et al.  Comparison of the FDA-Approved CDC DENV-1-4 Real-Time Reverse Transcription-PCR with a Laboratory-Developed Assay for Dengue Virus Detection and Serotyping , 2013, Journal of Clinical Microbiology.

[33]  J. Razzak,et al.  A comparison of WHO guidelines issued in 1997 and 2009 for dengue fever - single centre experience. , 2013, JPMA. The Journal of the Pakistan Medical Association.

[34]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[35]  A. Rudensky,et al.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.

[36]  O. Horstick,et al.  Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries , 2011, BMC infectious diseases.

[37]  D. Jans,et al.  Tumour necrosis factor alpha (TNF-alpha) stimulation of cells with established dengue virus type 2 infection induces cell death that is accompanied by a reduced ability of TNF-alpha to activate nuclear factor kappaB and reduced sphingosine kinase-1 activity. , 2011, The Journal of general virology.

[38]  B. Ryffel,et al.  Role of the Chemokine Receptors CCR1, CCR2 and CCR4 in the Pathogenesis of Experimental Dengue Infection in Mice , 2010, PloS one.

[39]  E. Harris,et al.  Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. , 2009, The American journal of tropical medicine and hygiene.

[40]  Kevin R Porter,et al.  Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. , 2009, Virology.

[41]  Mauricio L. Barreto,et al.  Recent Shift in Age Pattern of Dengue Hemorrhagic Fever, Brazil , 2008, Emerging infectious diseases.

[42]  E. Harris,et al.  Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. , 2008, Virology.

[43]  E. Riley,et al.  IL-10: The Master Regulator of Immunity to Infection , 2008, The Journal of Immunology.

[44]  J. Schlesinger,et al.  Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells , 2008, Journal of medical virology.

[45]  E. Harris,et al.  Dengue virus infects macrophages and dendritic cells in a mouse model of infection. , 2007, The Journal of infectious diseases.

[46]  N. M. Dung,et al.  Increased frequencies of CD4+CD25high regulatory T cells in acute dengue infection , 2007, The Journal of experimental medicine.

[47]  Trai-Ming Yeh,et al.  Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. , 2006, The American journal of tropical medicine and hygiene.

[48]  E. Harris,et al.  Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. , 2005, The American journal of tropical medicine and hygiene.

[49]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[50]  A. Nisalak,et al.  Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. , 2002, The Journal of infectious diseases.

[51]  S. Halstead,et al.  Effect of age on outcome of secondary dengue 2 infections. , 2002, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.